Combined use of FcγRIIb (CD32B) and CD20 specific antibodies
US11623005B2 · kind B2 · utility
0Cited by
10References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2019 |
| Grant date | Apr 11, 2023 |
| Priority date | — |
| Expiry date | May 10, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/507
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.